SLXN
Silexion Therapeutics CorpCompany with tickers: SLXN, SLXNW
CIK
2022416
CUSIP
G1281K130
Shares Outstanding
4,189,954
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,749,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $1,370,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-2,749,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-2,733,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $0.85 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $0.85 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |